Turkey Pharmaceuticals and Healthcare Report Q3 2017
BMI View: Turkey presents significant growth opportunities for multinational pharmaceutical firms, onaccount of its large, ageing population with a high and rapidly growing prevalence of non-communicablediseases. However, the country's regulatory environment and government's pharmaceutical policies willdeter innovative drugmakers, while the weakness of the lira will erode revenues. Nevertheless, the countryremains a key market in the region.
Highlighting Turkey's potential as a pharmaceutical exporter to the Europe region, Iranian drugmakerCinnaGen has invested in a drug production facility near Istanbul targeting greater access to internationalmarkets.
In April 2017, the Turkish Minister of Health announced that a cornerstone of the second phase of theHealth Transformation Programme will be a focus on reducing risk factors.
Highlighting the heavy investment into healthcare infrastructure, 33 new city hospitals will open in thecoming years, according to the Ministry of Health.